小儿多发性硬化症中的ofatumumab:一个病例系列
Wenlin Wu1, Yanping Ran1, Chi Hou1
1Department of Neurology, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou City, Guangdong Province, P.R. China.
Therapeutic advances in neurological disorders
|October 27, 2025
概括
奥法图马布 (OFA) 在治疗儿科多发性硬化症 (MS) 方面表现有前途. 这项小型研究发现,OFA在年轻的多发性硬化症患者中耐受性良好,并防止复发,这表明对这种疾病有潜在的益处.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
背景情况:
- 儿科发病多发性硬化症 (POMS) 是一种慢性中枢神经系统脱髓化疾病,影响约5%的MS病例.
- B细胞与POMS病原发生有关,因此针对B细胞的向疗法成为预防复发的重点.
研究的目的:
- 评估儿童多发性硬化症患者的非标签Ofatumumab (OFA) 的安全性和有效性.
- 评估OFA对复发率,MRI病变和这一队列中残疾进展的影响.
主要方法:
- 追溯病例系列分析了四名小儿多发性硬化症患者的临床数据,这些患者接受了OFA治疗.
- 数据包括患者年龄,治疗持续时间,OFA启动原因以及临床/MRI结果.
主要成果:
- 所有四名患者在OFA治疗期间都没有复发,没有新的MRI病变或EDSS进展.
- 与治疗前相比,OFA治疗后的每年复发率下降.
- 观察到B细胞枯竭,虽然不持续维持;一个患者出现了轻度,可控的不良事件.
结论:
- 在这个小小的小儿多发性硬化症患者队列中,Ofatumumab表现出良好的耐受性和潜在的疗效.
- 皮下给药提供了实际的优势.
- 需要进行更大规模的前性研究来证实这些发现并指导临床建议.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
240
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
240
Pharmacokinetics in Pediatric Patients: Drug Excretion
207
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
207
Pharmacokinetics in Pediatric Patients: Drug Distribution
251
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
251
Pharmacokinetics in Pediatric Patients: Drug Metabolism
189
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
189
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
227
Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
227


![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)